Pharmacokinetics of paclitaxel in an anephric patient

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s002800050868PMID 9923547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variability in human cytochrome P450 paclitaxel metabolism.

  1995cited by this paper
• Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

  1995cited by this paper
• Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

  1995cited by this paper
• Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.

  1994influential reference
• Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme.

  1994influential reference
• Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

  1994cited by this paper
• Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.

  1994influential reference
• Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.

  1994cited by this paper
• Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

  1994cited by this paper
• Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

  1993cited by this paper
• Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.

  1993cited by this paper
• Sequences of taxol and cisplatin: a phase I and pharmacologic study.

  1991cited by this paper
• Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

  1991cited by this paper
• A phase I trial of taxol given by a 6-hour intravenous infusion.

  1991cited by this paper
• Pharmacokinetics of vincristine in cancer patients treated with nifedipine

  1989cited by this paper
• Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

  1989cited by this paper
• Phase I clinical and pharmacokinetic study of taxol.

  1987cited by this paper
• High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.

  1987cited by this paper
• Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

  1987cited by this paper
• Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

  1987influential reference
• A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

  1985cited by this paper
• Cancer Research

  1965influential reference

• Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

  2023cites this paper
• Chemotherapy in chronic kidney disease and dialysis

  2020cites this paper
• Optimization and Absorption Mechanism of DHP 107 , Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy

  2018influential citation
• Interested in publishing with us ? Contact book

  2017cites this paper
• Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report.

  2016cites this paper
• Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis.

  2015cites this paper
• Carboplatin and weekly paclitaxel chemotherapy in hemodialysis patient with advanced lung cancer and severe comorbidity: effect of the drugs and their chemical intermediates

  2015cites this paper
• Gestion des chimiothérapies chez les patients hémodialysés

  2012cites this paper
• [Management of chemotherapy in hemodialysis patients].

  2012cites this paper
• A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel.

  2011cites this paper
• Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis

  2010cites this paper
• Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.

  2010cites this paper
• Lung cancer resection and adjuvant chemotherapy in a chronic renal failure patient

  2010cites this paper
• Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer.

  2009cites this paper
• Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

  2009cites this paper
• Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: A report from the National Wilms Tumor Study Group

  2008cites this paper
• Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

  2008cites this paper
• 血液透析患者に発症した肺腺癌に対してweekly Carboplatin＋Paclitaxel併用療法が奏効した1例

  2008cites this paper
• Inhibition of imatinib transport by uremic toxins during renal failure.

  2008cites this paper
• Dosing of cancer patients with low or absent renal function.

  2007cites this paper
• High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature

  2007cites this paper
• Systemic anticancer therapy in gynecological cancer patients with renal dysfunction

  2006cites this paper
• Taxanes in paediatric oncology: and now?

  2006cites this paper
• Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report.

  2006cites this paper
• Chemotherapy in Patients with Organ Dysfunction

  2006cites this paper
• Cancer management in patients with end-stage renal disease.

  2005cites this paper
• A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.

  2004cites this paper
• Effect of Haemodialysis on the Pharmacokinetics of Antineoplastic Drugs

  2004cites this paper
• Original article A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

  2004cites this paper
• Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis.

  2003cites this paper
• Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.

  2002cites this paper
• Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer

  2001cites this paper
• Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.

  1999cites this paper
• A Dialysis Patient with Pulmonary Adenocarcinoma Responded to the Weekly Carboplatin+Paclitaxel Combination

  year unknowncites this paper